Skip to main content

Ultra-Hypofractionated Radiotherapy Noninferior for Prostate Cancer

By Elana Gotkine HealthDay Reporter

Medically reviewed by Carmen Pope, BPharm. Last updated on May 8, 2025.

via HealthDay

THURSDAY, May 8, 2025 -- Ultra-hypofractionated (UHF) radiotherapy delivered over two weeks is noninferior to conventionally fractionated (CF) radiotherapy delivered over eight weeks for localized prostate cancer up to 10 years, according to a study presented at the annual meeting of the European Society for Radiotherapy and Oncology, held from May 2 to 6 in Vienna.

Per Nilsson, Ph.D., from Skåne University Hospital in Lund, Sweden, and colleagues presented the 10-year efficacy and toxicity outcomes for UHF versus CF radiotherapy for men with intermediate- to high-risk localized prostate cancer. The per-protocol population included 1,180 men who were randomly assigned to UHF (42.7 Gy in seven fractions over 2.5 weeks) or CF radiotherapy (78.0 Gy in 39 fractions over eight weeks).

The researchers found that 178 and 205 primary outcome events (failure-free survival [FFS]) occurred in the UHF and CF groups, respectively, at a median follow-up of 10.6 years. For FFS, the adjusted hazard ratio was 0.84 (95 percent confidence interval, 0.69 to 1.03), confirming noninferiority. Up to approximately six years, the Kaplan-Meier curves were similar, after which they diverged, favoring UHF. At 10 years, the difference was significant. The two groups had similar overall survival, which was 81 and 79 percent in the UHF and CF groups, respectively, at 10 years. The cumulative incidence of prostate cancer-specific death was identical, at 4 percent at 10 years. Freedom from androgen-deprivation therapy did not differ significantly between the groups and was 77 and 75 percent in the UHF and CF groups, respectively, at 10 years. There were no statistically significant differences in late genitourinary and gastrointestinal toxicity between the groups.

"Delivering fewer, higher doses over a shorter period works just as well as the standard approach -- not just in theory, but in real-world clinical practice," Nilsson said in a statement.

Press Release

More Information

Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

© 2025 HealthDay. All rights reserved.

Read this next

About One in Six Men With Grade Group 1 Prostate Cancer Has Intermediate-, High-Risk Disease

WEDNESDAY, Aug. 6, 2025 -- A proportion of men with grade group 1 (GG1) prostate cancer have a higher-risk disease than suggested by biopsy, according to a study published online...

Racial Differences Seen in Prostate Cancer Care Quality

WEDNESDAY, July 30, 2025 -- Black men with newly diagnosed prostate cancer have lower odds of overtreatment and confirmatory testing when compared with White men, according to a...

Low Rates of Isolated Locoregional Recurrence Seen in Young Women With Breast Cancer

TUESDAY, July 29, 2025 -- For women diagnosed with breast cancer at age 40 years or younger, the risk for isolated locoregional recurrence (LRR) is relatively low, according to a...

More news resources

Subscribe to our newsletter

Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.